4882.T
Perseus Proteomics Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 141.00
−0.70%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 140.0M | 135.0M | 120.0M | 100.0M | 94.0M |
| Cost of Revenue | 1.8M | 19.3M | 16.3M | 12.7M | 7.7M |
| Gross Profit | 21.7M | 116.2M | 104.1M | 87.7M | 86.5M |
| Operating Expenses | |||||
| R&D Expense | — | — | — | — | — |
| SG&A Expense | 240.0M | 861.1M | 930.5M | 982.4M | 784.3M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 240.0M | 861.1M | 930.5M | 982.4M | 784.3M |
| Cost and Expenses | 909.0M | 879.0M | 946.0M | 994.0M | 791.0M |
| Operating Income (EBIT) | (769.0M) | (744.0M) | (826.0M) | (894.0M) | (697.0M) |
| Non-Operating | |||||
| Interest Income | 744.0K | 5.0M | 2.0M | 46.0K | 55.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | 46.8M | 66.0M | (3.4M) | 15.3M | 8.2M |
| Non-Operating Income (excl Interest) | 52.4M | 67.4M | 1.8M | 21.1M | 8.1M |
| EBT (Pre-Tax Income) | (175.6M) | (716.2M) | (902.3M) | (1.1B) | (785.1M) |
| Income Tax Expense | 481.0K | 1.9M | 2.5M | 1.9M | 1.9M |
| Bottom Line | |||||
| Net Income | (757.0M) | (718.0M) | (904.0M) | (1.1B) | (786.0M) |
| Earnings from Cont. Ops | — | — | — | — | — |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (757.0M) | (718.0M) | (904.0M) | (1.1B) | (786.0M) |
| Per Share | |||||
| Basic EPS | (¥52) | (¥48) | (¥63) | (¥94) | (¥67) |
| Diluted EPS | (¥52) | (¥48) | — | — | — |
| Revenue Per Share | ¥9 | ¥9 | ¥8 | ¥8 | ¥8 |
| Shares | |||||
| Basic Shares Outstanding | 14.7M | 14.9M | 14.3M | 11.8M | 11.8M |
| Diluted Shares Outstanding | — | — | — | — | — |
| Profitability Metrics | |||||
| EBITDA | — | (743.6M) | (823.2M) | (890.5M) | (691.3M) |
| D&A | — | 382.0K | 2.8M | 3.5M | 5.7M |
| EBIT | (769.0M) | (744.0M) | (826.0M) | (894.0M) | (697.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026